REHOVOT, Israel, Nov. 03, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences:
- Stifel 2016 Healthcare Conference taking place in New York, from November 15 – 16, 2016. Dr. Lieberman’s presentation will take place on Tuesday, November 15 at 9:30am ET.
- Jefferies 2016 London Healthcare Conference taking place from November 16 – 17, 2016. Dr. Lieberman’s presentation will take place on Thursday, November 17 at 11:20am GMT, 6:20am ET.
To access the live webcasts of these presentations, please visit ir.neuroderm.com/. Replays will be available for one month following each presentation.
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. The company has three product candidates in different stages of development which offer a solution for almost every Parkinson’s disease patient from the moderate to the very severe stage of the disease. The company has developed a line of levodopa and carbidopa (LD/CD) product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD product candidates are ND0612L and ND0612H, which are used for treatment of moderate and advanced Parkinson’s disease patients, respectively, and which are delivered subcutaneously. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel.
Oded S. Lieberman, PhD, CEO
Tel.: +972-8-946 2729
Cell: +1-617-517 6077
U.S. Investor Contact:
Lazar Partners Ltd.